相似文献
1
Mortality Risk Stratification in Heart Failure. The Search for the Holy Grail Continues! Autonomic Nervous System Analysis is Back!
Arq Bras Cardiol. 2023 Feb;120(11):e20230761. doi: 10.36660/abc.20230761.
2
Heart Rate Turbulence Is a Powerful Predictor of Cardiac Death and Ventricular Arrhythmias in Postmyocardial Infarction and Heart Failure Patients: A Systematic Review and Meta-Analysis.
Circ Arrhythm Electrophysiol. 2016 Dec;9(12). doi: 10.1161/CIRCEP.116.004610.
3
A Simple Prognostic Index Based on Heart Rate, Age, and Systolic Blood Pressure for the Risk Stratification of Heart Failure With Preserved Ejection Fraction.
Heart Lung Circ. 2025 Sep;34(9):883-890. doi: 10.1016/j.hlc.2025.03.007. Epub 2025 Jun 30.
4
The Use of Metabolomes in Risk Stratification of Heart Failure Patients: Protocol for a Scoping Review.
JMIR Res Protoc. 2024 May 23;13:e53905. doi: 10.2196/53905.
5
Angiotensin Receptor-Neprilysin Inhibitor Is Associated With Improved Cardiac Autonomic Function in Heart Failure.
J Am Heart Assoc. 2024 Aug 6;13(15):e033538. doi: 10.1161/JAHA.123.033538. Epub 2024 Jul 31.
6
Association between ultra-short-term heart rate variability and atrial fibrillation in heart failure population: a protocol for a prospective observational cohort study.
BMJ Open. 2025 Aug 1;15(7):e101170. doi: 10.1136/bmjopen-2025-101170.
7
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Cochrane Database Syst Rev. 2018 Jun 28;6(6):CD012721. doi: 10.1002/14651858.CD012721.pub2.
8
Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.
Cochrane Database Syst Rev. 2016 Jul 8;7(7):CD009077. doi: 10.1002/14651858.CD009077.pub3.
9
Heart Rate Variability's Value in Predicting Out-of-Hospital Major Adverse Cardiovascular Events in Patients With Chronic Heart Failure.
Cardiovasc Ther. 2025 Aug 14;2025:6412775. doi: 10.1155/cdr/6412775. eCollection 2025.
10
Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy.
Cochrane Database Syst Rev. 2012 Nov 14;11:CD009077. doi: 10.1002/14651858.CD009077.pub2.
引用本文的文献
1
Is it Fair to Contraindicate Cardiac Defibrillator Implantation for Patients with Socioeconomic or Psychological Vulnerability?
Arq Bras Cardiol. 2024 Dec 2;121(10):e20240643. doi: 10.36660/abc.20240643. eCollection 2024.
本文引用的文献
1
Predictive Model of All-Cause Death in Patients with Heart Failure using Heart Rate Variability.
Arq Bras Cardiol. 2023 Nov;120(11):e20220379. doi: 10.36660/abc.20220379.
2
[Not Available].
Arq Bras Cardiol. 2018 Sep;111(3):436-539. doi: 10.5935/abc.20180190.
3
Development and Validation of Predictive Models of Cardiac Mortality and Transplantation in Resynchronization Therapy.
Arq Bras Cardiol. 2015 Oct;105(4):399-409. doi: 10.5935/abc.20150093. Epub 2015 Aug 7.
4
Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure.
JACC Heart Fail. 2014 Oct;2(5):429-36. doi: 10.1016/j.jchf.2014.04.006. Epub 2014 Sep 3.
5
Prediction of heart rate variability on cardiac sudden death in heart failure patients: a systematic review.
Int J Cardiol. 2014 Jul 1;174(3):857-860. doi: 10.1016/j.ijcard.2014.04.176. Epub 2014 Apr 26.
6
Long-term follow-up of patients with chronic chagas disease and implantable cardioverter-defibrillator.
Pacing Clin Electrophysiol. 2014 Jun;37(6):751-6. doi: 10.1111/pace.12342. Epub 2014 Jan 27.
7
Relation of short-term heart rate variability to incident heart failure (from the Multi-Ethnic Study of Atherosclerosis).
Am J Cardiol. 2013 Aug 15;112(4):533-40. doi: 10.1016/j.amjcard.2013.04.018. Epub 2013 May 16.
8
A quantitative systematic review of normal values for short-term heart rate variability in healthy adults.
Pacing Clin Electrophysiol. 2010 Nov;33(11):1407-17. doi: 10.1111/j.1540-8159.2010.02841.x.
9
Statistical models and patient predictors of readmission for heart failure: a systematic review.
Arch Intern Med. 2008 Jul 14;168(13):1371-86. doi: 10.1001/archinte.168.13.1371.
10
Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator.
Circulation. 2005 May 17;111(19):2537-49; discussion 2537-49.
Zotero 插件